Every 10-Q that Zura Bio Limited (ZURA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ZURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZURA filings page.
Zura Bio Limited is a clinical-stage biotechnology company focused on autoimmune and inflammatory diseases, advancing lead antibody tibulizumab through Phase 2 trials in hidradenitis suppurativa and diffuse cutaneous systemic sclerosis, with additional programs in torudokimab and crebankitug under evaluation.
For the three months ended June 30, 2026, Zura reported a net loss of $26.3 million, and for the six months a net loss of $50.5 million, reflecting higher research and development spending as Phase 2 programs ramped. Research and development expenses rose to $20.7 million in the quarter and $35.5 million year-to-date, largely driven by tibulizumab clinical trial and manufacturing costs and increased R&D headcount. General and administrative expenses were $8.6 million in the quarter and $19.4 million for the six months.
Cash and cash equivalents were $205.1 million as of June 30, 2026, up from $109.4 million at year-end 2025, primarily due to the February 2026 equity offering, which generated approximately $134.6 million in net proceeds from issuing 21.2 million Class A Ordinary Shares and 1.8 million pre-funded warrants. Total assets were $213.4 million and shareholders’ equity $197.1 million, with management stating current liquidity is sufficient to fund operations through at least the end of 2028.
Zura Bio Limited reported a larger net loss as it invested heavily in clinical development while strengthening its balance sheet. For the three months ended March 31, 2026, net loss was $24.2 million compared with $17.4 million a year earlier, driven by higher research and development and administrative costs.
Research and development expenses rose to $14.7 million, mainly from Phase 2 trials of lead antibody tibulizumab in hidradenitis suppurativa and systemic sclerosis. General and administrative expenses increased to $10.8 million as the company expanded its public-company and corporate infrastructure.
Zura closed a February 2026 equity offering of Class A shares and pre-funded warrants, generating net proceeds of about $134.6 million. Cash and cash equivalents grew to $225.6 million, and management believes this should fund operations through at least the end of 2028 while it advances multiple autoimmune and inflammatory disease programs.
Zura Bio Limited reported its Q3 2025 results. Cash and cash equivalents were $139.0 million as of September 30, 2025, compared with $176.5 million at year-end 2024. The company recorded a net loss of $18.0 million for the quarter and $51.5 million for the nine months, reflecting ongoing investment in clinical programs.
Quarterly operating expenses were $19.5 million, with research and development at $11.9 million and general and administrative at $7.6 million. Net cash used in operating activities was $42.5 million for the nine months. Management states it should have sufficient liquidity to fund operations over the next twelve months.
The pipeline centers on Phase 2 development of tibulizumab (ZB-106), a dual IL‑17A/BAFF bispecific antibody. During 2025, the company sold 3,000,000 shares under its ATM at $1.75 for $5.1 million in net proceeds. Class A Ordinary Shares outstanding were 65,018,058 as of September 30, 2025, and 65,023,308 as of November 10, 2025.
Zura Bio Limited reported advancing clinical programs while continuing to operate at a loss. As of June 30, 2025 the company held $154.5 million in cash and cash equivalents and reported a net loss of $15.993 million for the three months ended June 30, 2025 and $33.435 million for the six months ended June 30, 2025, leaving an accumulated deficit of $189.3 million. The balance sheet shows total assets of $157.8 million and total shareholders' equity of $127.4 million.
The company is a clinical-stage immunology company developing tibulizumab (ZB-106), which entered a global Phase 2 study TibuSHIELD in May 2025 (~180 adults) and previously initiated TibuSURE (Dec 2024, ~80 participants). Zura also lists two other clinical assets, crebankitug and torudokimab. The filing discloses contingent milestone and royalty obligations under multiple license agreements and a pending $5.0 million invoice related to a finder’s fee that the company is reviewing. Management states it expects existing liquidity to fund operations for the next twelve months.